Fundraising FoxAmadeus Capital Partners — 2023 Investments
6 investments dated 2023 · listed companies and verified rows first · show all
Secondmind provides AI-powered software to help automotive engineers accelerate vehicle design and development.
AI & Machine LearningDeep TechSaaSCambridge, GB
Carl Edward Rasmussen(Chief Science Officer)inGary Brotman(Chief Executive Officer & Founder)in
Co-investorsCambridge Innovation CapitalAtlantic Bridge VenturesPassion CapitalReefknot InvestmentsSingapore Innovate Pte. Ltd.
Paragraf develops graphene-based electronic devices, including molecular sensors (electrolyte-gated field-effect transistors) for biosensing and chemical sensing, and Hall effect sensors for current, position, and magnetic field measurement at cryogenic temperatures.
Deep TechNew MaterialsSemiconductorsCambridgeshire, GB
Simon Thomas(Chief Executive Officer of the issuer.)in
Co-investorsBlack Opal VenturesCambridge Angels groupEMV CapitalIn-Q-TelIQ CapitalMartlet Capital+5 more
.jpeg){kind=logo}
RoboK offers SiteLens®, an AI computer vision platform that analyzes existing CCTV footage to detect workplace hazards, monitor PPE compliance, identify near misses, and generate safety KPI and compliance reports.
Advanced ManufacturingAI & Machine LearningLogistics & Supply Chain
Co-investorsAI SeedCambridge Angels groupEMV CapitalMartlet CapitalUniversity of Cambridge Enterprise
Seldon provides a Kubernetes-native MLOps and LLMOps platform for deploying, scaling, and governing machine learning and AI models in production across any cloud or on-premise environment.
AI & Machine LearningCloud ComputingDeveloper ToolsLondon, GB
Co-investorsAlbionVCBright Pixel CapitalCambridge Innovation CapitalGlobal BrainTechstarsThundermark Capital+1 more
Tenzo provides data analytics and business intelligence software for restaurant operators to monitor performance and optimize operations.
Cloud ComputingDeveloper ToolsEnterprise SoftwareFoodTechRetail TechSaaSLondon, GB
Christian Mouysset(Co-founder & CEO)Adam Taylor(Co-founder & CTO)in
Co-investorsTechstarsS28 Capital
TILT Biotherapeutics develops an investigational adenoviral immunotherapy platform for treating solid tumor cancers, with late-stage development of TILT-123 for head and neck cancer treatment.
BiotechHealthtechMedical DevicesHelsinki, FI
Akseli Hemminki(Founder and CEO)in
Co-investorsLifeline VenturesTesi (Finnish Industry Investment Ltd)
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.